rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation could be demonstrated at significantly lower rates in cases of PTC + HT (32.1 vs 60.7%, p < 0.005).
|
30666518 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation could be demonstrated at significantly lower rates in cases of PTC + HT (32.1 vs 60.7%, p < 0.005).
|
30666518 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto's Thyroiditis.
|
28687736 |
2017 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto's Thyroiditis.
|
28687736 |
2017 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The pooled analysis indicated that age<45 years (OR = 1.57, 95%CI:1.48-1.66, P < 0.001), male gender (OR = 1.79, 95%CI: 1.69-1.91, P < 0.001), tumor size>10 mm (OR = 2.61, 95%CI:2.27-3.00, P < 0.001), bilaterality (OR = 1.52, 95%CI:1.31-1.77, P < 0.001), multifocality (OR = 1.46, 95%CI: 1.31-1.61, P < 0.001), extracapsular invasion (OR = 2.10, 95%CI:1.81-2.43, P < 0.001), angiolymphatic invasion (OR = 8.02, 95%CI:5.00-12.87, P < 0.001), high histologic risk (OR = 2.62, 95%CI:2.13-3.22, P < 0.001) and BRAF(V600E) mutation (OR:1.78, 95%CI:1.38-2.30, P < 0.001) were significantly associated with CLNM, and upper third location (OR = 0.54, 95%CI:0.43-0.67, P < 0.001) and lymphocytic thyroiditis (OR = 0.64, 95%CI:0.42-0.97, P = 0.034) were decreased risk factors of CLNM.
|
26944586 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Hashimoto's thyroiditis and BRAF(V600E) status may help to predict clinical outcome of PTC.
|
25213729 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In addition, Hashimoto's thyroiditis was related to less lymph node metastasis and extrathyroidal extension in PTCs with BRAF(V600E) mutation.
|
26041461 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This meta-analysis confirmed significant associations between BRAF(V600E) mutation and female gender, multifocality, ETE, LNM, TNM stage, concomitant hashimoto thyroiditis, vascular invasion and recurrence/persistence, suggesting the predictive value of BRAF(V600E) mutation for PTC prognosis.
|
26871894 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.
|
26598713 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Hashimoto's thyroiditis and BRAF(V600E) status may help to predict clinical outcome of PTC.
|
25213729 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This meta-analysis confirmed significant associations between BRAF(V600E) mutation and female gender, multifocality, ETE, LNM, TNM stage, concomitant hashimoto thyroiditis, vascular invasion and recurrence/persistence, suggesting the predictive value of BRAF(V600E) mutation for PTC prognosis.
|
26871894 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.
|
26598713 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The pooled analysis indicated that age<45 years (OR = 1.57, 95%CI:1.48-1.66, P < 0.001), male gender (OR = 1.79, 95%CI: 1.69-1.91, P < 0.001), tumor size>10 mm (OR = 2.61, 95%CI:2.27-3.00, P < 0.001), bilaterality (OR = 1.52, 95%CI:1.31-1.77, P < 0.001), multifocality (OR = 1.46, 95%CI: 1.31-1.61, P < 0.001), extracapsular invasion (OR = 2.10, 95%CI:1.81-2.43, P < 0.001), angiolymphatic invasion (OR = 8.02, 95%CI:5.00-12.87, P < 0.001), high histologic risk (OR = 2.62, 95%CI:2.13-3.22, P < 0.001) and BRAF(V600E) mutation (OR:1.78, 95%CI:1.38-2.30, P < 0.001) were significantly associated with CLNM, and upper third location (OR = 0.54, 95%CI:0.43-0.67, P < 0.001) and lymphocytic thyroiditis (OR = 0.64, 95%CI:0.42-0.97, P = 0.034) were decreased risk factors of CLNM.
|
26944586 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In addition, Hashimoto's thyroiditis was related to less lymph node metastasis and extrathyroidal extension in PTCs with BRAF(V600E) mutation.
|
26041461 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results show that HT in patients with PTC is associated with a low probability of BRAF (V600E) mutations.
|
25312294 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results show that HT in patients with PTC is associated with a low probability of BRAF (V600E) mutations.
|
25312294 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These results indicate that BRAF(V600E) assessment by pyrosequencing is a reliable assay useful to refine inconclusive cytology of thyroid nodules also in the presence of concurrent HT.
|
23775008 |
2014 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These results indicate that BRAF(V600E) assessment by pyrosequencing is a reliable assay useful to refine inconclusive cytology of thyroid nodules also in the presence of concurrent HT.
|
23775008 |
2014 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) mutation is associated with a more advanced PTC at diagnosis; however, its role in the clinicopathological characteristics of PTC with concurrent HT is unknown.
|
23469895 |
2013 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) mutation is associated with a more advanced PTC at diagnosis; however, its role in the clinicopathological characteristics of PTC with concurrent HT is unknown.
|
23469895 |
2013 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.
|
19014278 |
2009 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.
|
19014278 |
2009 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Screening for activating BRAF mutations in a series of 83 PTCs identified the most common V600E mutation in 39 cases (histologically, 38 classic PTCs and 1 sclerosing variant PTC) and a complex in-frame mutation involving amino acids V600-S605 in a stage III multicentric follicular variant PTC, occurring in a 50-year-old female patient, who was affected by hypothyroidism in autoimmune thyroiditis and had a family history of PTC and autoimmune thyroiditis.
|
18426810 |
2008 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Screening for activating BRAF mutations in a series of 83 PTCs identified the most common V600E mutation in 39 cases (histologically, 38 classic PTCs and 1 sclerosing variant PTC) and a complex in-frame mutation involving amino acids V600-S605 in a stage III multicentric follicular variant PTC, occurring in a 50-year-old female patient, who was affected by hypothyroidism in autoimmune thyroiditis and had a family history of PTC and autoimmune thyroiditis.
|
18426810 |
2008 |
rs231775
|
|
|
0.090 |
GeneticVariation |
BEFREE |
The genetic variation in CTLA-4 gene with reference to rs231775 polymorphism contributes to an increased predisposition to HT and GD.
|
30771152 |
2019 |